NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

We spoke to the first author of a new study that could challenge much of what we thought we knew about Alzheimer’s disease.

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

A scan that can detect Alzheimer’s disease before memory loss begins is now available in the UAE for the first time. The amyloid PET scan, recently launched at Cleveland Clinic Abu Dhabi, is a ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

TAMPA, Fla. — The Food and Drug Administration has granted accelerated approval to the experimental drug lecanemab, shown to slow down the progression of Alzheimer’s disease in its early ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's plan to slash research spending could delay or halt progress for years, ...

A simple blood test for insulin resistance could help predict cognitive decline in people with early Alzheimer’s.

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal ...

A once-a-day pill called blarcamesine may slow memory loss and preserve independence—without the scary side effects or ...